Isomorphic Labs in talks to raise about $5 billion for AI drug discovery
Alphabet-owned Isomorphic Labs is seeking about $5 billion for AI-based drug discovery, according to Bloomberg, while Dealroom reports a $50 billion valuation. Speaking at Bloomberg Tech in London on 2 November, the company's president discussed the promise of the approach, but its own candidates have not yet been tested in humans, with first trials expected by the end of 2026.
Who is affected and how
- pharmaceuticals
- The fundraising could intensify competition among AI-native players for partnerships and talent, and the first human trials will serve as a benchmark.
Sources
- Isomorphic Labs in Talks for About $5 Billion in Funding - Bloombergbloomberg.com · Nov 4, 2026
- Alphabet's Isomorphic Labs in negotiations for a $5 billion funding round | KuCoinkucoin.com · Nov 4, 2026
- Isomorphic Labs in Talks for 5 Billion Dollars at 50 Billion Dollar Valuation, Bloomberg Reportstrendingtopics.eu · Nov 5, 2026
- Isomorphic Labs in talks to raise £3.7bn, Bloomberg saysresultsense.com · Nov 5, 2026
- Isomorphic Labs in talks for $5B round at $50B valuation | AI Weeklyaiweekly.co · Nov 5, 2026
- Isomorphic Labs Seeks $5B at $50B Valuation for AI Drugs | TechRobusttechrobust.com · Nov 5, 2026
- Isomorphic Labs president: All drugs will be AI-designedrdworldonline.com · Nov 6, 2026
- DeepMind spinout Isomorphic Labs in talks to raise about $5B at a $50B valuation | Dealroom Newsdealroom.co · Nov 4, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.